Eli Lilly and Company $LLY Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 13.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,453 shares of the company’s stock after selling 51,837 shares during the period. Eli Lilly and Company makes up approximately 0.7% of Rockefeller Capital Management L.P.’s portfolio, making the stock its 20th biggest holding. Rockefeller Capital Management L.P.’s holdings in Eli Lilly and Company were worth $269,292,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $27,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $35,000. TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $55,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,024.67 on Friday. The firm has a market cap of $968.70 billion, a PE ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,033.62. The company has a fifty day moving average price of $826.89 and a 200 day moving average price of $780.14. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Wall Street Analyst Weigh In

A number of analysts have commented on LLY shares. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,015.11.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.